Ocriplasmin: who is the best candidate?
Claudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ocriplasmin-who-is-the-best-candidate-peer-reviewed-article-OPTH |
| _version_ | 1818740854519496704 |
|---|---|
| author | Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB |
| author_facet | Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB |
| author_sort | Prospero Ponce CM |
| collection | DOAJ |
| description | Claudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating vitreomacular traction and full-thickness macular hole. Induction of posterior vitreous detachment is an active area of developmental clinical and basic research. Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. There are several unexplored areas of intervention where enzymatic vitreolysis could potentially be used (ie, diabetic macular edema). Recent promising studies have included combinations of enzymatic approaches and new synthetic molecules that induce complete posterior vitreous detachment as well as antiangiogenesis. Although no guidelines have been proposed for the use of ocriplasmin, this review attempts to aid physicians in answering the most important question, “Who is the best candidate?” Keywords: vitreomacular traction, macular hole, enzymatic vitreolysis, ocriplasmin-best candidate, diabetic macular edema, future management |
| first_indexed | 2024-12-18T01:47:21Z |
| format | Article |
| id | doaj.art-513dc210827f4837993822f0cad7cf35 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-18T01:47:21Z |
| publishDate | 2016-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-513dc210827f4837993822f0cad7cf352022-12-21T21:25:08ZengDove Medical PressClinical Ophthalmology1177-54832016-03-012016Issue 148549526044Ocriplasmin: who is the best candidate?Prospero Ponce CMStevenson WGelman RAgarwal DRChristoforidis JBClaudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating vitreomacular traction and full-thickness macular hole. Induction of posterior vitreous detachment is an active area of developmental clinical and basic research. Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. There are several unexplored areas of intervention where enzymatic vitreolysis could potentially be used (ie, diabetic macular edema). Recent promising studies have included combinations of enzymatic approaches and new synthetic molecules that induce complete posterior vitreous detachment as well as antiangiogenesis. Although no guidelines have been proposed for the use of ocriplasmin, this review attempts to aid physicians in answering the most important question, “Who is the best candidate?” Keywords: vitreomacular traction, macular hole, enzymatic vitreolysis, ocriplasmin-best candidate, diabetic macular edema, future managementhttps://www.dovepress.com/ocriplasmin-who-is-the-best-candidate-peer-reviewed-article-OPTHVitreomacular tractionMacular HoleEnzymatic vitreolysisOcriplasmin-Best candidateDiabetic macular edemafuture management |
| spellingShingle | Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB Ocriplasmin: who is the best candidate? Clinical Ophthalmology Vitreomacular traction Macular Hole Enzymatic vitreolysis Ocriplasmin-Best candidate Diabetic macular edema future management |
| title | Ocriplasmin: who is the best candidate? |
| title_full | Ocriplasmin: who is the best candidate? |
| title_fullStr | Ocriplasmin: who is the best candidate? |
| title_full_unstemmed | Ocriplasmin: who is the best candidate? |
| title_short | Ocriplasmin: who is the best candidate? |
| title_sort | ocriplasmin who is the best candidate |
| topic | Vitreomacular traction Macular Hole Enzymatic vitreolysis Ocriplasmin-Best candidate Diabetic macular edema future management |
| url | https://www.dovepress.com/ocriplasmin-who-is-the-best-candidate-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT prosperoponcecm ocriplasminwhoisthebestcandidate AT stevensonw ocriplasminwhoisthebestcandidate AT gelmanr ocriplasminwhoisthebestcandidate AT agarwaldr ocriplasminwhoisthebestcandidate AT christoforidisjb ocriplasminwhoisthebestcandidate |